Emma Agnew

Dr. Emma Agnew

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LHLuis Hortells
Luis Hortells
IVIñigo Valiente-Alandi
Iñigo Valiente-Alandi
ZTZachary M. Thomas
Zachary M. Thomas
EAEmma Agnew
Emma Agnew
DSDan J. Schnell
Dan J. Schnell
Katherine YutzeyKatherine Yutzey
Katherine Yutzey
During the postnatal period in mammals, the cardiac muscle transitions from hyperplasic to hypertrophic growth, the extracellular matrix (ECM) undergoes remodeling, and the heart loses regenerative capacity. While ECM maturation and crosstalk between cardiac fibroblasts (CFs) and cardiomyocytes (CMs) have been implicated in neonatal heart development, not much is known about specialized fibroblast heterogeneity and function in the early postnatal period. In order to better understand CF functions in heart maturation and postnatal cardiomyocyte cell-cycle arrest, we have performed gene expression profiling and ablation of postnatal CF populations. Fibroblast lineages expressing Tcf21 or Periostin were traced in transgenic GFP reporter mice, and their biological functions and transitions during the postnatal period were examined in sorted cells using RNA sequencing. Highly proliferative Periostin (Postn)+ lineage CFs were found from postnatal day 1 (P1) to P11 but were not detected at P30, due to a repression of Postn gene expression. This population was less abundant and transcriptionally different from Tcf21+ resident CFs. The specialized Postn+ population preferentially expresses genes related to cell proliferation and neuronal development, while Tcf21+ CFs differentially express genes related to ECM maturation at P7 and immune crosstalk at P30. Ablation of the Postn+ CFs from P0 to P6 led to altered cardiac sympathetic nerve patterning and a reduction in binucleation and hypertrophic growth with increased fetal troponin (TroponinI1) expression in CM. Thus, postnatal CFs are heterogeneous and include a transient proliferative Postn+ population required for cardiac nerve development and cardiomyocyte maturation soon after birth. Significance During the postnatal period, the heart undergoes important changes, including cardiomyocyte cell-cycle arrest and loss of regenerative capacity. While other cell types have been better characterized, the information related to postnatal cardiac fibroblasts (CFs) is limited. Here, we report a specialized population of highly proliferative periostin-expressing (Postn+) fibroblasts in the early postnatal heart that become quiescent at P30. In comparison, P7 Tcf21+ fibroblasts have distinct gene expression from Postn+ CFs. Notably, Postn+ CFs express proliferation and neuronal-related genes, while Tcf21+ CFs preferentially express extracellular-matrix–related genes. Ablation of Postn+ cells leads to reduced cardiomyocyte growth, mitotic activity, and binucleation with increased sympathetic nerve area. Thus Postn+ cells represent a specialized developmental CF population critical for postnatal cardiac maturation.

1 July 2018 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
EAEmma Agnew
Emma Agnew
JIJessica R Ivy
Jessica R Ivy
SSSarah J Stock
Sarah J Stock
KCKaren E Chapman
Karen E Chapman
Glucocorticoids are essential in mammals to mature fetal organs and tissues in order to survive after birth. Hence, antenatal glucocorticoid treatment (termed antenatal corticosteroid therapy) can be life-saving in preterm babies and is commonly used in women at risk of preterm birth. While the effects of glucocorticoids on lung maturation have been well described, the effects on the fetal heart remain less clear. Experiments in mice have shown that endogenous glucocorticoid action is required to mature the fetal heart. However, whether the potent synthetic glucocorticoids used in antenatal corticosteroid therapy have similar maturational effects on the fetal heart is less clear. Moreover, antenatal corticosteroid therapy may increase the risk of cardiovascular disease in adulthood. Here, we present a narrative review of the evidence relating to the effects of antenatal glucocorticoid action on the fetal heart and discuss the implications for antenatal corticosteroid therapy.

22 July 2020 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
NVNivedhitha Velayutham
Nivedhitha Velayutham
CAChristina M. Alfieri
Christina M. Alfieri
EAEmma Agnew
Emma Agnew
KRKyle W. Riggs
Kyle W. Riggs
RBR. Scott Baker
R. Scott Baker
Katherine YutzeyKatherine Yutzey
Katherine Yutzey

25 July 2019 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
Nivedhitha VelayuthamNivedhitha Velayutham
Nivedhitha Velayutham
EAEmma Agnew
Emma Agnew
Katherine YutzeyKatherine Yutzey
Katherine Yutzey

30 September 2021 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
JIJessica R. Ivy
Jessica R. Ivy
RCRoderic N. Carter
Roderic N. Carter
JZJin‐Feng Zhao
Jin‐Feng Zhao
CBCharlotte Buckley
Charlotte Buckley
HUHelena Urquijo
Helena Urquijo
KCKaren E. Chapman
Karen E. Chapman
The late gestational rise in glucocorticoids contributes to the structural and functional maturation of the perinatal heart. Here, we hypothesized that glucocorticoid action contributes to the metabolic switch in perinatal cardiomyocytes from carbohydrate to fatty acid oxidation. In primary mouse fetal cardiomyocytes, dexamethasone treatment induced expression of genes involved in fatty acid oxidation and increased mitochondrial oxidation of palmitate, dependent upon a glucocorticoid receptor (GR). Dexamethasone did not, however, induce mitophagy or alter the morphology of the mitochondrial network. In vivo, in neonatal mice, dexamethasone treatment induced cardiac expression of fatty acid oxidation genes. However, dexamethasone treatment of pregnant C57Bl/6 mice at embryonic day (E)13.5 or E16.5 failed to induce fatty acid oxidation genes in fetal hearts assessed 24 h later. Instead, at E17.5, fatty acid oxidation genes were downregulated by dexamethasone, as was GR itself. PGC‐1α, required for glucocorticoid‐induced maturation of primary mouse fetal cardiomyocytes in vitro, was also downregulated in fetal hearts at E17.5, 24 h after dexamethasone administration. Similarly, following a course of antenatal corticosteroids in a translational sheep model of preterm birth, both GR and PGC‐1α were downregulated in heart. These data suggest that endogenous glucocorticoids support the perinatal switch to fatty acid oxidation in cardiomyocytes through changes in gene expression rather than gross changes in mitochondrial volume or mitochondrial turnover. Moreover, our data suggest that treatment with exogenous glucocorticoids may interfere with normal fetal heart maturation, possibly by downregulating GR. This has implications for clinical use of antenatal corticosteroids when preterm birth is considered a possibility.Key points: Glucocorticoids are steroid hormones that play a vital role in late pregnancy in maturing fetal organs, including the heart. In fetal cardiomyocytes in culture, glucocorticoids promote mitochondrial fatty acid oxidation, suggesting they facilitate the perinatal switch from carbohydrates to fatty acids as the predominant energy substrate. Administration of a synthetic glucocorticoid in late pregnancy in mice downregulates the glucocorticoid receptor and interferes with the normal increase in genes involved in fatty acid metabolism in the heart. In a sheep model of preterm birth, antenatal corticosteroids (synthetic glucocorticoid) downregulates the glucocorticoid receptor and the gene encoding PGC‐1α, a master regulator of energy metabolism. These experiments suggest that administration of antenatal corticosteroids in anticipation of preterm delivery may interfere with fetal heart maturation by downregulating the ability to respond to glucocorticoids.

1 June 2019 in Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
EAEmma Agnew
Emma Agnew
AGA Garcia-Burgos
A Garcia-Burgos
RRR V Richardson
R V Richardson
HMH Manos
H Manos
ATA J W Thomson
A J W Thomson
KCK E Chapman
K E Chapman
Endogenous glucocorticoid action is important in the structural and functional maturation of the fetal heart. In fetal mice, although glucocorticoid concentrations are extremely low before E14.5, glucocorticoid receptor (GR) is expressed in the heart from E10.5. To investigate whether activation of cardiac GR prior to E14.5 induces precocious fetal heart maturation, we administered dexamethasone in the drinking water of pregnant dams from E12.5-E15.5. To test direct effects of glucocorticoids upon the cardiovascular system we used SMGRKO mice, with Sm22-Cre-mediated disruption of GR in cardiomyocytes and vascular smooth muscle. Contrary to expectations, echocardiography showed no advancement of functional maturation of the fetal heart. Moreover, litter size was decreased 2 days following cessation of antenatal glucocorticoid exposure, irrespective of fetal genotype. The myocardial performance index and E/A wave ratio, markers of fetal heart maturation, were not significantly affected by dexamethasone treatment in either genotype. Dexamethasone treatment transiently decreased the myocardial deceleration index (MDI; a marker of diastolic function), in control fetuses at E15.5, with recovery by E17.5, 2 days after cessation of treatment. MDI was lower in SMGRKO than in control fetuses and was unaffected by dexamethasone. The transient decrease in MDI was associated with repression of cardiac GR in control fetuses following dexamethasone treatment. Measurement of glucocorticoid levels in fetal tissue and hypothalamic corticotropin-releasing hormone (Crh) mRNA levels suggest complex and differential effects of dexamethasone treatment upon the hypothalamic-pituitary-adrenal axis between genotypes. These data suggest potentially detrimental and direct effects of antenatal glucocorticoid treatment upon fetal heart function.